ERGO Perspective: HMA dispute resolution in India; indemnities in cross-border M&A transactions; and more
Hotel management agreements (HMA) are typically long-term contracts between a hotel owner and an expert operator with significant financial implications for the owner because the performance of the agreement determines hotel cash flow and therefore hotel value. For these reasons, mechanisms to resolve disputes are very important in order to achieve contractual efficacy and efficiency.
Unfortunately, this is an area that is very often neglected in these contracts, until it is too late. This paper is timely because based on our experience the current difficult operating environment in India is straining owner/operator relationships and is conducive of disputes…
Click on the link below to read the rest of the Khaitan & Co briefing.
Sign in or Register to continue reading this article
It's quick, easy and free!
It takes just 5 minutes to register. Answer a few simple questions and once completed you’ll have instant access.Register now
Why register to The Lawyer
In-depth, expert analysis into the stories behind the headlines from our leading team of journalists.
Identify the major players and business opportunities within a particular region through our series of free, special reports.
Receive your pick of The Lawyer's daily and weekly email newsletters, tailored by practice area, region and job function.
More relevant to you
To continue providing the best analysis, insight and news across the legal market we are collecting some information about who you are, what you do and where you work to improve The Lawyer and make it more relevant to you.
News from Khaitan & Co
Briefings from Khaitan & Co
Newsletter: energy, infrastructure and resources — Reserve Bank permits long-term structuring of new long-term project loans to infrastructure and core industries; and more
Khaitan & Co has released the 15 July 2014 edition of its energy, infrastructure and resources newsletter.
The Indian Patent Office has issued guidelines so as to bring about uniformity in the examination of pharmaceutical patent applications.